CSIMarket
 
Alkermes Plc   (ALKS)
Other Ticker:  
 
 
Price: $27.5300 $-1.22 -4.243%
Day's High: $28.79 Week Perf: -3.3 %
Day's Low: $ 27.48 30 Day Perf: -15.45 %
Volume (M): 2,263 52 Wk High: $ 33.71
Volume (M$): $ 62,306 52 Wk Avg: $28.46
Open: $28.58 52 Wk Low: $22.01



 Market Capitalization (Millions $) 4,732
 Shares Outstanding (Millions) 172
 Employees 2,500
 Revenues (TTM) (Millions $) 1,591
 Net Income (TTM) (Millions $) 215
 Cash Flow (TTM) (Millions $) 384
 Capital Exp. (TTM) (Millions $) 41

Alkermes Plc
Alkermes Plc is a biopharmaceutical company that specializes in developing innovative medicines to address unmet medical needs in large therapeutic categories. The company was founded in 1987 and is headquartered in Dublin, Ireland, with additional operations and research facilities in the United States and Europe.

Alkermes is focused on developing treatments for serious and chronic diseases including addiction, schizophrenia, opioid use disorder, and CNS disorders. The company offers a broad range of products and technologies that enable the development of novel therapies, including drug delivery systems, manufacturing technologies, and analytical capabilities.

The company's product portfolio includes VIVITROL for Alcohol Dependence, ARISTADA for Schizophrenia, RISPERDAL CONSTA for Schizophrenia and Bipolar Disorder, and BYDUREON for Type 2 Diabetes, among others. Alkermes has also been actively pursuing the development of new treatments for opioid addiction and overdose, including ALKS 5461 and ALKS 3831.

Alkermes has a highly experienced research and development team that is dedicated to advancing the science of drug development. The company is committed to investing in new technologies and platforms that can help to accelerate the pace of discovery and bring new treatments to patients in need.

Alkermes Plc is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol "ALKS". The company has a strong track record of growth and continues to expand its global presence through strategic partnerships, acquisitions, and collaborations.


   Company Address: Connaught House Dublin 4 0
   Company Phone Number: 1-772-8000   Stock Exchange / Ticker: NASDAQ ALKS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Alkermes Plc

Alkermes Plc: Surging Profits Amidst the Changing Tides of Pharmaceutical Industry



Alkermes Plc, a major player in the pharmaceutical preparations industry, has recently reported its financial results for the third quarter of fiscal year 2023. With positive bottom-line growth, increased revenue, improved profit margins, and notable developments in key financial indicators, the company appears to be on a positive trajectory. This article aims to analyze the impact of these results and explore the potential implications for Alkermes Plc moving forward.
1. Strong Financial Performance:
During the July to September 30, 2023 fiscal interval, Alkermes Plc achieved positive bottom-line growth, with a profit of $0.28 per share compared to a loss of $-0.39 per share in the same period last year. This indicates a significant improvement in the company's financial position and reflects efficient cost management and operational effectiveness.

Alkermes Plc

Alkermes Plc Showcases Remarkable 123.517% Revenue Jump Despite EPS Downturn in Q2 2023

Alkermes Plc: Strong Revenue Growth and Improved Profit Margins Boost Investor Confidence
Alkermes Plc, a leading biopharmaceutical company, has reported impressive financial results for the period ending June 30, 2023, showcasing a remarkable revenue growth of 123.517% year on year to reach $617.40 million. This substantial increase in revenue was driven by a doubling of revenue by 114.676%, reaching $287.60 million, compared to the previous reporting season.
One of the most significant developments for Alkermes Plc was the turnaround in income, as the company exhibited earnings per share of $1.38, in stark contrast to the preceding reporting season when net profit per share was at $-0.25. This positive shift demonstrates the company's ability to generate substantial profits while meeting market expectations.






 

Alkermes Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com